Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 29.

Nowicka, A M; Häuselmann, I; Borsig, L; Bolduan, S; Schindler, M; Schraml, P; Heikenwalder, M; Moch, H (2016). A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization. Oncogene, 35(24):3125-3138.

Wyler, L; Napoli, C U; Ingold, B; Sulser, T; Heikenwälder, M; Schraml, P; Moch, H (2014). Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression. British Journal of Cancer, 110(3):686-694.

Roth, P; Silginer, M; Goodman, S L; Hasenbach, K; Thies, S; Maurer, G; Schraml, P; Tabatabai, G; Moch, H; Tritschler, I; Weller, M (2013). Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain, 136(2):564-576.

Vogetseder, A; Thies, S; Ingold, B; Roth, P; Weller, M; Schraml, P; Goodman, S L; Moch, H (2013). αv-Integrin isoform expression in primary human tumors and brain metastases. International Journal of Cancer, 133(10):2362-2371.

Morra, L; Rechsteiner, M; Casagrande, S; von Teichman, A; Schraml, P; Moch, H; Soltermann, A (2012). Characterization of periostin isoform pattern in non-small cell lung cancer. Lung Cancer, 76(2):183-190.

Denkert, C; Kronenwett, R; Schlake, W; Bohmann, K; Penzel, R; Weber, K E; Höfler, H; Lehmann, U; Schirmacher, P; Specht, K; Rudas, M; Kreipe, H H; Schraml, P; Schlake, G; Bago-Horvath, Z; Tiecke, F; Varga, Z; Moch, H; Schmidt, M; Prinzler, J; Kerjaschki, D; Sinn, B V; Müller, B M; Filipits, M; Petry, C; Dietel, M (2012). Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Archiv, 460(3):251-259.

Wiedl, T; Collaud, S; Hillinger, S; Arni, S; Burgess, C; Kroll, W; Schraml, P; Soltermann, A; Moch, H; Weder, W (2012). KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma. Cancer Genomics & Proteomics, 9(1):51-54.

Stiehl, D P; Bordoli, M R; Abreu-Rodríguez, I; Wollenick, K; Schraml, P; Gradin, K; Poellinger, L; Kristiansen, G; Wenger, R H (2012). Non-canonical HIF-2alpha function drives autonomous breast cancer cell growth via an AREG-EGFR/ErbB4 autocrine loop. Oncogene, 31(18):2283-2297.

Schraml, P; von Teichman, A; Mihic-Probst, D; Simcock, M; Ochsenbein, A; Dummer, R; Michieilin, O; Seifert, B; Schläppi, M; Moch, H; von Moos, R (2012). Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncology Reports, 28(2):654-658.

Wollenick, K; Hu, J; Kristiansen, G; Schraml, P; Rehrauer, H; Berchner-Pfannschmidt, U; Fandrey, J; Wenger, R H; Stiehl, D P (2012). Synthetic transactivation screening reveals ETV4 as broad coactivator of hypoxia-inducible factor signaling. Nucleic Acids Research, 40(5):1928-1943.

Suwaki, N; Vanhecke, E; Atkins, K M; Graf, M; Swabey, K; Huang, P; Schraml, P; Moch, H; Cassidy, A M; Brewer, D; Al-Lazikani, B; Workman, P; De-Bono, J; Kaye, S B; Larkin, J; Gore, M E; Sawyers, C L; Nelson, P; Beer, T M; Geng, H; Gao, L; Qian, D Z; Alumkal, J J; Thomas, G; Thomas, G V (2011). A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Science Translational Medicine, 3(85):85ra47.

Doberstein, K; Schramme, A; Lee, S B; Blaheta, R A; Wedel, S; Moch, H; Schraml, P; Pfeilschifter, J; Kristiansen, G; Gutwein, P (2011). L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. Carcinogenesis, 32(3):262-270.

Bordoli, M R; Stiehl, D P; Borsig, L; Kristiansen, G; Hausladen, S; Schraml, P; Wenger, R H; Camenisch, G (2011). Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis. Oncogene, 30(5):548-560.

Morra, L; Rechsteiner, M; Casagrande, S; Duc Luu, V; Santimaria, R; Diener, P A; Sulser, T; Kristiansen, G; Schraml, P; Moch, H; Soltermann, A (2011). Relevance of periostin splice variants in renal cell carcinoma. American Journal of Pathology, 179(3):1513-1521.

Rechsteiner, M P; von Teichman, A; Nowicka, A; Sulser, T; Schraml, P; Moch, H (2011). VHL gene mutations and their effects on hypoxia inducible factor HIF{alpha}: Identification of potential driver and passenger mutations. Cancer Research, 71(16):5500-5511.

Teichman, A V; Compérat, E; Behnke, S; Storz, M; Moch, H; Schraml, P (2011). VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma. Modern Pathology, 24(4):571-578.

Probst-Hensch, N M; Steiner, J H B; Schraml, P; Varga, Z; Zürrer-Härdi, U; Storz, M; Korol, D; Fehr, M K; Fink, D; Pestalozzi, B C; Lütolf, U M; Theurillat, J P; Moch, H (2010). IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clinical Cancer Research, 16(3):1025-1032.

Dahinden, C; Ingold, B; Wild, P; Boysen, G; Luu, V D; Montani, M; Kristiansen, G; Sulser, T; Bühlmann, P; Moch, H; Schraml, P (2010). Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clinical Cancer Research, 16(1):88-98.

Tischler, V; Fritzsche, F R; Wild, P J; Stephan, C; Seifert, H H; Riener, M O; Hermanns, T; Mortezavi, A; Gerhardt, J; Schraml, P; Jung, K; Moch, H; Soltermann, A; Kristiansen, G (2010). Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer, 10:273.

Balamurugan, K; Luu, V D; Kaufmann, M R; Hofmann, V S; Boysen, G; Barth, S; Bordoli, M R; Stiehl, D P; Moch, H; Schraml, P; Wenger, R H; Camenisch, G (2009). Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response. Oncogene:1-12.

Ingold, B; Schraml, P; Heppner, F L; Moch, H (2009). Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. PLoS ONE, 4(3):e4775.

Boysen, G; Wollscheid, B; Bausch-Fluck, D; Schraml, P; Moch, H (2009). Identifizierung VHL-assoziierter Veränderungen im klarzelligen Nierenzellkarzinom : Anwendung von kombinierten Genom- und Expressionsanalysen. Der Pathologe, Suppl 2:188-192.

Luu, V D; Boysen, G; Struckmann, K; Casagrande, S; von Teichman, A; Wild, P J; Sulser, T; Schraml, P; Moch, H (2009). Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clinical Cancer Research, 15(10):3297-3304.

Steu, S; Baucamp, M; von Dach, G; Bawohl, M; Dettwiler, S; Storz, M; Moch, H; Schraml, P (2008). A procedure for tissue freezing and processing applicable to both intra-operative frozen section diagnosis and tissue banking in surgical pathology. Virchows Archiv, 452(3):305-312.

Schraml, P; Frew, I J; Thoma, C R; Boysen, G; Struckmann, K; Krek, W; Moch, H (2008). Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. Modern Pathology, 22(1):31-36.

Luu, V D; Fischer, B; von Teichman, A; Boysen, G; Mertz, K; Zimmermann, P; Moch, H; Schraml, P (2008). Von-Hippel-Lindau-Gen-Mutationstypen: Assoziation mit Genexpressionssignaturen in klarzelligen Nierenzellkarzinomen. Der Pathologe, 29(Suppl.):303-307.

Struckmann, K; Mertz, K; Steu, S; Storz, M; Staller, P; Krek, W; Schraml, P; Moch, H (2008). pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. Journal of Pathology, 214(4):464-471.

Zhao, J; Yart, A; Frigerio, S; Perren, A; Schraml, P; Weisstanner, C; Stallmach, T; Krek, W; Moch, H (2007). Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene. Oncogene, 26(23):3440-3449.

Mihic-Probst, D; Kuster, A; Kilgus, S; Bode-Lesniewska, B; Ingold-Heppner, B; Leung, C; Storz, M; Seifert, Burkhardt; Marino, S; Schraml, P; Dummer, R; Moch, H (2007). Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. International Journal of Cancer, 121(8):1764-1770.

This list was generated on Fri Dec 15 17:25:54 2017 CET.